After management's discussion, there will be a question and answer session. Please be advised that today's conference call is being recorded. Before we begin, I will now take a moment to read statements about forward looking statements.
This call and the question-and-answer session that follows it contains forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 2 thousand and other federal securities law. Words such as expects, anticipates, intends, plan, believe, seeks, estimates and similar expressions or variations of such words are intended to identify forward looking statements. For example, we are using forward looking statements in this presentation when we discuss the continuing growth and sustainability of commercial adoption and utilization of ProSense.
The expansion of the company's U. And international commercial presence, anticipated enrollment of the first patients in and continued expansion of the CHOICE study, the potential for clinical evidence and commercial utilization to support physician confidence reimbursement initiatives and broader market adoption. The company's commercialization efforts in Japan, the plan used for its financial resources and the company's ability to execute its long term growth strategy and create sustainable long term shareholder value.
The forward looking statements contained or implied during this call are subject to other risks and uncertainties, many of which are beyond the control of the company, including those set forth in the Risk Factors section of the company's annual report on Form 20 F for the year ended 12/31/2025, filed with the SEC on 03/17/2026. Is available on the SEC's website www.sec.com. The company disclaims any intention or obligation, except as required by law, to update or advise any forward looking statements whether because of new information, future events or otherwise.
This conference call contains time sensitive information and speaks only as of the live broadcast today. 08/12/2026. I will now turn the call over to iQ Medical's CEO, Eyal Shamir. Eyal Shamir: Thank you, operator, and thank you, everyone, for joining us today.
The first half of 2026 marks an important inflection point for IQ. Over the past several years, we have focused on building the clinical regulatory and scientific foundation for ProSense. We invested in generating clinical evidence achieving important regulatory milestones and educating physician around the world.
Extract — continue reading at the source.
